Total Payments
$2,800
2024 Payments
$455.29
Companies
31
Transactions
155
Medicare Patients
14,115
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$2,800 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,800 | 155 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $476.86 | 25 | $0 (2024) |
| Amgen Inc. | $385.20 | 21 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $381.45 | 22 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $240.74 | 14 | $0 (2023) |
| PFIZER INC. | $172.07 | 10 | $0 (2024) |
| Novo Nordisk Inc | $123.22 | 6 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $112.47 | 6 | $0 (2023) |
| Esperion Therapeutics, Inc. | $103.54 | 6 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $96.68 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $71.60 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $455.29 | 27 | Novartis Pharmaceuticals Corporation ($140.53) |
| 2023 | $996.00 | 49 | Merck Sharp & Dohme LLC ($240.07) |
| 2022 | $383.53 | 21 | Merck Sharp & Dohme LLC ($121.93) |
| 2021 | $285.50 | 17 | Esperion Therapeutics, Inc. ($65.72) |
| 2020 | $67.69 | 4 | Amgen Inc. ($35.04) |
| 2019 | $160.27 | 9 | Medtronic Vascular, Inc. ($38.05) |
| 2018 | $219.05 | 14 | Amgen Inc. ($66.86) |
| 2017 | $232.54 | 14 | Amgen Inc. ($59.33) |
All Payment Transactions
155 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $4.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/13/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Not Applicable | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $10.66 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.16 | General |
| Category: Cardiovascular | ||||||
| 08/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Cardiology | ||||||
| 08/21/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $33.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/03/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/26/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $24.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $9.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Cardiology | ||||||
| 05/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/26/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/06/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Cardiology | ||||||
| 03/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/04/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Cardiology | ||||||
| 02/27/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/21/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/16/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $7.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/07/2024 | MEDICOMP INC | TELEPATCH CARDIAC MONITOR (Device) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: CARDIOLOGY | ||||||
| 02/02/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Not Applicable | ||||||
| 01/31/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 3,406 | 4,371 | $1.3M | $304,636 |
| 2022 | 18 | 3,747 | 4,845 | $1.4M | $347,510 |
| 2021 | 17 | 3,620 | 4,677 | $1.4M | $379,546 |
| 2020 | 17 | 3,342 | 4,395 | $1.2M | $320,955 |
Total Patients
14,115
Total Services
18,288
Medicare Billing
$1.4M
Procedure Codes
80
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 518 | 845 | $256,880 | $79,135 | 30.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 339 | 345 | $231,495 | $51,481 | 22.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 123 | 123 | $177,120 | $42,587 | 24.0% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 123 | 224 | $122,016 | $21,990 | 18.0% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 131 | 131 | $74,539 | $21,344 | 28.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 116 | 116 | $54,056 | $14,252 | 26.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 140 | 202 | $40,198 | $13,193 | 32.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 70 | 277 | $42,381 | $11,664 | 27.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 68 | 68 | $25,908 | $7,208 | 27.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 139 | 141 | $36,660 | $7,021 | 19.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 790 | 964 | $71,191 | $6,177 | 8.7% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 29 | 29 | $37,874 | $6,037 | 15.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 476 | 547 | $36,649 | $5,934 | 16.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 76 | $15,656 | $5,313 | 33.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 19 | 20 | $15,300 | $3,696 | 24.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 48 | 49 | $25,431 | $2,751 | 10.8% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 19 | 19 | $12,787 | $2,670 | 20.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 117 | 117 | $8,541 | $1,331 | 15.6% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2023 | 23 | 24 | $1,872 | $344.70 | 18.4% |
| 93225 | Electrocardiogram (ecg) 2-day continuous | Office | 2023 | 23 | 24 | $2,376 | $322.98 | 13.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 26 | 30 | $715.50 | $182.99 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 518 | 836 | $254,468 | $80,334 | 31.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 173 | 173 | $249,120 | $64,989 | 26.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 305 | 313 | $210,023 | $49,268 | 23.5% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2022 | 172 | 298 | $140,664 | $28,287 | 20.1% |
About Dr. Bhanumathi Krishnan, MD
Dr. Bhanumathi Krishnan, MD is a Cardiovascular Disease healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730281395.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bhanumathi Krishnan, MD has received a total of $2,800 in payments from pharmaceutical and medical device companies, with $455.29 received in 2024. These payments were reported across 155 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($2,800).
As a Medicare-enrolled provider, Krishnan has provided services to 14,115 Medicare beneficiaries, totaling 18,288 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Fairfax, VA
- Active Since 09/03/2006
- Last Updated 12/15/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1730281395
Products in Payments
- VERQUVO (Drug) $476.86
- ENTRESTO (Drug) $311.00
- Repatha (Biological) $276.46
- XARELTO (Drug) $240.74
- ELIQUIS (Drug) $187.21
- Corlanor (Drug) $108.74
- NEXLETOL (Drug) $103.54
- LEQVIO (Drug) $70.45
- FARXIGA (Drug) $64.23
- MULTAQ (Drug) $61.43
- Vascepa (Drug) $56.86
- Rybelsus (Drug) $56.29
- Livalo (Drug) $51.30
- PRALUENT (Drug) $51.04
- TELEPATCH CARDIAC MONITOR (Device) $50.12
- Ozempic (Drug) $42.88
- VYNDAQEL (Drug) $42.73
- PRADAXA (Drug) $40.42
- Azure (Device) $38.05
- Arcalyst (Drug) $36.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Fairfax
Abbas Emaminia, Md, MD
Cardiovascular Disease — Payments: $20,669
Cardiovascular Disease $20,669
Gautam Ramakrishna, M.d, M.D
Cardiovascular Disease — Payments: $7,216
Cardiovascular Disease $7,216
Dr. Cristobal Goa, M.d, M.D
Cardiovascular Disease — Payments: $6,651
Cardiovascular Disease $6,651
Dr. Casey Benton, M.d, M.D
Cardiovascular Disease — Payments: $5,867
Cardiovascular Disease $5,867
Michael Banihashemi, Md, MD
Cardiovascular Disease — Payments: $4,723
Cardiovascular Disease $4,723
Dr. Kenneth Brooks, Md, MD
Cardiovascular Disease — Payments: $4,187
Cardiovascular Disease $4,187